サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751022

ヒト呼吸器合胞体ウイルス治療の世界市場レポート 2025年

Human Respiratory Syncytial Virus Treatment Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
ヒト呼吸器合胞体ウイルス治療の世界市場レポート 2025年
出版日: 2025年06月17日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒト呼吸器合胞体ウイルス治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で25億8,000万米ドルに成長します。この予測期間における成長は、モノクローナル抗体に対する需要の高まり、RSVワクチン開発への投資の増加、早期診断への注目の高まり、発展途上地域におけるヘルスケアへのアクセス拡大、新規治療に対する規制当局の承認などに起因しています。予測期間における主な動向には、長時間作用型RSV抗体の開発、併用療法への注力、AIを活用したRSVの創薬、呼吸器感染症に対する遠隔医療の利用拡大、RSV治療薬開発のための製薬企業との提携などがあります。

遠隔医療ソリューションの成長は、今後数年間、ヒト呼吸器合胞体ウイルス（RSV）治療市場の拡大を促進すると予想されます。テレヘルスとは、通信技術を通じて遠隔での診察、診断、モニタリング、治療を可能にするデジタルヘルスケアサービスを指します。遠隔診療を可能にし、従来の医療施設の負担を軽減するデジタルヘルスケア技術の利用拡大により、遠隔医療ソリューションの採用が増加しています。RSV治療のための遠隔医療は、遠隔モニタリング、早期発見、バーチャルコンサルテーションをサポートし、対面での通院の必要性を最小限に抑えながら、患者のケアを改善します。例えば、米国を拠点とする政府情報プロバイダーTelehealth.HHS.govによると、2023年第4四半期のテレヘルスの利用者は約2,188万3,731人に達し、第3四半期から13％増加し、さらに278万3,159人の利用者が増加しました。このように、遠隔医療ソリューションの台頭がRSV治療市場の成長に寄与しています。

ヒト呼吸器合胞体ウイルス治療市場の主要企業は、競争力を維持するために、モノクローナル抗体や抗ウイルス薬などの革新的な治療法の開発に注力しています。モノクローナル抗体は、身体が感染症と闘うのを助ける実験室で作られたタンパク質であり、抗ウイルス薬はウイルスの増殖や拡散を防ぐように設計されています。例えば、2023年7月、英国のバイオ医薬品会社アストラゼネカは、フランスの製薬会社サノフィS.A.と提携し、乳幼児およびハイリスク小児におけるRSV下気道疾患の予防を目的としたモノクローナル抗体ベイフォルタス（ニルセビマブ・アリップ）の米国食品医薬品局（FDA）承認を発表しました。この承認は、RSV予防における重要な進歩であり、ベイフォルタスは、RSVシーズン中、受動免疫を提供する長時間作用型の単回投与治療薬です。特に、重症のRSV感染症に最もかかりやすい新生児や乳児に有益であり、入院や合併症を減らすことができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界ヒト呼吸器合胞体ウイルス治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のヒト呼吸器合胞体ウイルス治療市場：成長率分析
  • 世界のヒト呼吸器合胞体ウイルス治療市場の実績：規模と成長, 2019-2024
  • 世界のヒト呼吸器合胞体ウイルス治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界ヒト呼吸器合胞体ウイルス治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のヒト呼吸器合胞体ウイルス治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗ウイルス薬
  • モノクローナル抗体
  • ワクチン
  • 支持療法
  • 世界のヒト呼吸器合胞体ウイルス治療市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 小児患者
  • 成人患者
  • 世界のヒト呼吸器合胞体ウイルス治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オーラル
  • 非経口
  • 世界のヒト呼吸器合胞体ウイルス治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • クリニック
  • ホームケア
  • 世界のヒト呼吸器合胞体ウイルス治療市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 融合阻害剤
  • ヌクレオシド類似体
  • RNAポリメラーゼ阻害剤
  • 世界のヒト呼吸器合胞体ウイルス治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • パリビズマブ
  • ニルセビマブ
  • その他のRSV特異的モノクローナル抗体
  • 世界のヒト呼吸器合胞体ウイルス治療市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 生弱毒化ワクチン
  • サブユニットワクチン
  • mRNAベースのワクチン
  • ベクターベースのワクチン
  • 世界のヒト呼吸器合胞体ウイルス治療市場支持療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 酸素療法
  • 機械的人工呼吸器
  • 水分補給療法
  • 発熱と疼痛管理

第7章 地域別・国別分析

  • 世界のヒト呼吸器合胞体ウイルス治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のヒト呼吸器合胞体ウイルス治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ヒト呼吸器合胞体ウイルス治療市場：競合情勢
  • ヒト呼吸器合胞体ウイルス治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Johnson & Johnson
  • Moderna Inc.
  • Kyowa Kirin Co. Ltd.
  • Novavax Inc.
  • Alnylam Pharmaceuticals Inc.
  • AdVaccine Biotechnology Co. Ltd.
  • Enanta Pharmaceuticals Inc.
  • Aridis Pharmaceuticals Inc.
  • Synairgen plc
  • VBI Vaccines Inc.
  • SAB Biotherapeutics Inc.
  • Meissa Vaccines Inc.
  • Osivax SAS
  • Codagenix Inc.
  • BioVaxys Technology Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ヒト呼吸器合胞体ウイルス治療市場2029：新たな機会を提供する国
  • ヒト呼吸器合胞体ウイルス治療市場2029：新たな機会を提供するセグメント
  • ヒト呼吸器合胞体ウイルス治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34875

Human respiratory syncytial virus (RSV) treatment focuses on managing symptoms and preventing complications, especially in vulnerable populations. It typically involves supportive care to alleviate breathing difficulties, reduce fever, and ensure adequate hydration. In severe cases, hospitalization may be necessary for oxygen therapy and close monitoring. Prevention strategies are also essential in minimizing the risk of infection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary treatment types for human respiratory syncytial virus are antiviral medications, monoclonal antibodies, vaccines, and supportive care. Antiviral medications are designed to treat viral infections by inhibiting virus replication, thereby reducing the severity and duration of illness and preventing complications. Treatment is administered to both pediatric and adult patients, with various routes of administration including oral and parenteral. These treatments are provided by several end-users, such as hospitals, clinics, and home care settings.

The human respiratory syncytial virus treatment market research report is one of a series of new reports from The Business Research Company that provides human respiratory syncytial virus treatment market statistics, including the human respiratory syncytial virus treatment industry global market size, regional shares, competitors with the human respiratory syncytial virus treatment market share, detailed human respiratory syncytial virus treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the human respiratory syncytial virus treatment industry. These human respiratory syncytial virus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human respiratory syncytial virus treatment market size has grown strongly in recent years. It will grow from$1.69 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to rising RSV infection rates, an increase in the infant and elderly populations, a growth in hospital admissions due to respiratory illnesses, government vaccination programs, and heightened awareness of RSV complications.

The human respiratory syncytial virus treatment market size is expected to see strong growth in the next few years. It will grow to$2.58 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to the rising demand for monoclonal antibodies, increasing investment in RSV vaccine development, a growing focus on early diagnosis, expanding access to healthcare in developing regions, and regulatory approvals for new treatments. Key trends in the forecast period include the development of long-acting RSV antibodies, a focus on combination therapies, AI-driven drug discovery for RSV, the growing use of telemedicine for respiratory infections, and pharmaceutical collaborations for RSV drug development.

The growth of telehealth solutions is expected to drive the expansion of the human respiratory syncytial virus (RSV) treatment market in the coming years. Telehealth refers to digital healthcare services that allow for remote consultations, diagnosis, monitoring, and treatment through telecommunication technologies. The adoption of telehealth solutions is increasing, driven by the growing use of digital healthcare technologies, which enable remote care and ease the burden on traditional healthcare facilities. Telehealth for RSV treatment supports remote monitoring, early detection, and virtual consultations, improving patient care while minimizing the need for in-person hospital visits. For instance, according to Telehealth.HHS.gov, a US-based government information provider, telehealth usage in the fourth quarter of 2023 reached approximately 21,883,731 users, reflecting a 13% increase from the third quarter, with an additional 2,783,159 users. Thus, the rise of telehealth solutions is contributing to the growth of the RSV treatment market.

Leading companies in the human respiratory syncytial virus treatment market are focusing on developing innovative therapies, such as monoclonal antibodies and antiviral drugs, to maintain a competitive edge. Monoclonal antibodies are lab-engineered proteins that help the body combat infections, while antiviral drugs are designed to prevent viruses from multiplying or spreading. For example, in July 2023, AstraZeneca plc, a UK-based biopharmaceutical company, partnered with Sanofi S.A., a French pharmaceutical company, to announce the U.S. Food and Drug Administration (FDA) approval of Beyfortus (nirsevimab-alip), a monoclonal antibody aimed at preventing RSV lower respiratory tract disease in infants and high-risk children. This approval marked a significant advancement in RSV prevention, as Beyfortus offers a long-acting, single-dose treatment that provides passive immunity throughout the RSV season. It is particularly beneficial for newborns and infants, who are most vulnerable to severe RSV infections, reducing hospitalizations and complications.

In June 2022, Pfizer Inc., a US-based pharmaceutical company, acquired ReViral Ltd. for $525 million. This acquisition strengthens Pfizer's infectious disease portfolio and accelerates the development of innovative antiviral therapies for respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in developing treatments specifically for RSV.

Major players in the human respiratory syncytial virus treatment market are Pfizer Inc., Merck & Co, Sanofi S.A., AstraZeneca plc, GSK plc, Johnson & Johnson, Moderna Inc., Kyowa Kirin Co. Ltd., Novavax Inc., Alnylam Pharmaceuticals Inc., AdVaccine Biotechnology Co. Ltd., Enanta Pharmaceuticals Inc., Aridis Pharmaceuticals Inc., Synairgen plc, VBI Vaccines Inc., SAB Biotherapeutics Inc., Meissa Vaccines Inc., Osivax SAS, Codagenix Inc., and BioVaxys Technology Corp.

North America was the largest region in the human respiratory syncytial virus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human respiratory syncytial virus treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human respiratory syncytial virus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human respiratory syncytial virus treatment market consists of revenues earned by entities by providing services such as oxygen therapy, mechanical ventilation, hydration therapy, and fever and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The human respiratory syncytial virus treatment market also includes sales of medications, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Respiratory Syncytial Virus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human respiratory syncytial virus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human respiratory syncytial virus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human respiratory syncytial virus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Antiviral Medications; Monoclonal Antibodies; Vaccines; Supportive Care
  • 2) By Patient Type: Pediatric Patients; Adult Patients
  • 3) By Route Of Administration: Oral; Parenteral
  • 4) By End User: Hospitals; Clinics; Home Care
  • Subsegments:
  • 1) By Antiviral Medications: Fusion Inhibitors; Nucleoside Analogues; RNA Polymerase Inhibitors
  • 2) By Monoclonal Antibodies: Palivizumab; Nirsevimab; Other RSV-Specific Monoclonal Antibodies
  • 3) By Vaccines: Live Attenuated Vaccines; Subunit Vaccines; mRNA-Based Vaccines; Vector-Based Vaccines
  • 4) By Supportive Care: Oxygen Therapy; Mechanical Ventilation; Hydration Therapy; Fever and Pain Management
  • Companies Mentioned: Pfizer Inc.; Merck & Co; Sanofi S.A.; AstraZeneca plc; GSK plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Respiratory Syncytial Virus Treatment Market Characteristics

3. Human Respiratory Syncytial Virus Treatment Market Trends And Strategies

4. Human Respiratory Syncytial Virus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Respiratory Syncytial Virus Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Human Respiratory Syncytial Virus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Human Respiratory Syncytial Virus Treatment Market Growth Rate Analysis
  • 5.4. Global Human Respiratory Syncytial Virus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Human Respiratory Syncytial Virus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Human Respiratory Syncytial Virus Treatment Total Addressable Market (TAM)

6. Human Respiratory Syncytial Virus Treatment Market Segmentation

  • 6.1. Global Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antiviral Medications
  • Monoclonal Antibodies
  • Vaccines
  • Supportive Care
  • 6.2. Global Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric Patients
  • Adult Patients
  • 6.3. Global Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • 6.4. Global Human Respiratory Syncytial Virus Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Home Care
  • 6.5. Global Human Respiratory Syncytial Virus Treatment Market, Sub-Segmentation Of Antiviral Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fusion Inhibitors
  • Nucleoside Analogues
  • RNA Polymerase Inhibitors
  • 6.6. Global Human Respiratory Syncytial Virus Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Palivizumab
  • Nirsevimab
  • Other RSV-Specific Monoclonal Antibodies
  • 6.7. Global Human Respiratory Syncytial Virus Treatment Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Live Attenuated Vaccines
  • Subunit Vaccines
  • mRNA-Based Vaccines
  • Vector-Based Vaccines
  • 6.8. Global Human Respiratory Syncytial Virus Treatment Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oxygen Therapy
  • Mechanical Ventilation
  • Hydration Therapy
  • Fever And Pain Management

7. Human Respiratory Syncytial Virus Treatment Market Regional And Country Analysis

  • 7.1. Global Human Respiratory Syncytial Virus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Human Respiratory Syncytial Virus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market

  • 8.1. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Respiratory Syncytial Virus Treatment Market

  • 9.1. China Human Respiratory Syncytial Virus Treatment Market Overview
  • 9.2. China Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Respiratory Syncytial Virus Treatment Market

  • 10.1. India Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Respiratory Syncytial Virus Treatment Market

  • 11.1. Japan Human Respiratory Syncytial Virus Treatment Market Overview
  • 11.2. Japan Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Respiratory Syncytial Virus Treatment Market

  • 12.1. Australia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Respiratory Syncytial Virus Treatment Market

  • 13.1. Indonesia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Respiratory Syncytial Virus Treatment Market

  • 14.1. South Korea Human Respiratory Syncytial Virus Treatment Market Overview
  • 14.2. South Korea Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Respiratory Syncytial Virus Treatment Market

  • 15.1. Western Europe Human Respiratory Syncytial Virus Treatment Market Overview
  • 15.2. Western Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Respiratory Syncytial Virus Treatment Market

  • 16.1. UK Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Respiratory Syncytial Virus Treatment Market

  • 17.1. Germany Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Respiratory Syncytial Virus Treatment Market

  • 18.1. France Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Respiratory Syncytial Virus Treatment Market

  • 19.1. Italy Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Respiratory Syncytial Virus Treatment Market

  • 20.1. Spain Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Respiratory Syncytial Virus Treatment Market

  • 21.1. Eastern Europe Human Respiratory Syncytial Virus Treatment Market Overview
  • 21.2. Eastern Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Respiratory Syncytial Virus Treatment Market

  • 22.1. Russia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Respiratory Syncytial Virus Treatment Market

  • 23.1. North America Human Respiratory Syncytial Virus Treatment Market Overview
  • 23.2. North America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Respiratory Syncytial Virus Treatment Market

  • 24.1. USA Human Respiratory Syncytial Virus Treatment Market Overview
  • 24.2. USA Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Respiratory Syncytial Virus Treatment Market

  • 25.1. Canada Human Respiratory Syncytial Virus Treatment Market Overview
  • 25.2. Canada Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Respiratory Syncytial Virus Treatment Market

  • 26.1. South America Human Respiratory Syncytial Virus Treatment Market Overview
  • 26.2. South America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Respiratory Syncytial Virus Treatment Market

  • 27.1. Brazil Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Respiratory Syncytial Virus Treatment Market

  • 28.1. Middle East Human Respiratory Syncytial Virus Treatment Market Overview
  • 28.2. Middle East Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Respiratory Syncytial Virus Treatment Market

  • 29.1. Africa Human Respiratory Syncytial Virus Treatment Market Overview
  • 29.2. Africa Human Respiratory Syncytial Virus Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Human Respiratory Syncytial Virus Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Human Respiratory Syncytial Virus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Respiratory Syncytial Virus Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Human Respiratory Syncytial Virus Treatment Market Competitive Landscape
  • 30.2. Human Respiratory Syncytial Virus Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Human Respiratory Syncytial Virus Treatment Market Other Major And Innovative Companies

  • 31.1. Johnson & Johnson
  • 31.2. Moderna Inc.
  • 31.3. Kyowa Kirin Co. Ltd.
  • 31.4. Novavax Inc.
  • 31.5. Alnylam Pharmaceuticals Inc.
  • 31.6. AdVaccine Biotechnology Co. Ltd.
  • 31.7. Enanta Pharmaceuticals Inc.
  • 31.8. Aridis Pharmaceuticals Inc.
  • 31.9. Synairgen plc
  • 31.10. VBI Vaccines Inc.
  • 31.11. SAB Biotherapeutics Inc.
  • 31.12. Meissa Vaccines Inc.
  • 31.13. Osivax SAS
  • 31.14. Codagenix Inc.
  • 31.15. BioVaxys Technology Corp.

32. Global Human Respiratory Syncytial Virus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Respiratory Syncytial Virus Treatment Market

34. Recent Developments In The Human Respiratory Syncytial Virus Treatment Market

35. Human Respiratory Syncytial Virus Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Human Respiratory Syncytial Virus Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Human Respiratory Syncytial Virus Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Human Respiratory Syncytial Virus Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
  • 250617_r34875_Human_Respiratory_Syncytial_Virus_Treatment_GMR_2025